Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 2/20 | 0.60 |
| ▸ | FABP3 | P05413 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26847268 | 0.87 | FABP4 (0.63) | FABP4FABP3MEN1KMT2ARAB9A | |
| SCHEMBL23850130 | 0.84 | FABP4 (0.69) | FABP4FABP3MEN1KMT2ARAB9A | |
| SCHEMBL26848024 | 0.82 | LMNA (0.57) | MAPTPKMTSHRGFERGPR84 | |
| SCHEMBL24087938 | 0.75 | FABP4 (0.52) | FABP4FABP3MEN1KMT2ARAB9A | |
| SCHEMBL26847229 | 0.75 | FABP3 (0.64) | FABP4FABP3MEN1KMT2ARAB9A | |
| SCHEMBL26847241 | 0.75 | HPGD (0.64) | FABP4FABP3MEN1KMT2ARAB9A | |
| SCHEMBL23849882 | 0.75 | ACMSD (0.67) | FABP4FABP3MEN1KMT2ARAB9A | |
| SCHEMBL31053425 | 0.75 | ACMSD (0.67) | FABP4FABP3MEN1KMT2ARAB9A | |
| SCHEMBL23849821 | 0.75 | MEN1 (0.57) | FABP4FABP3MEN1KMT2ARAB9A | |
| SCHEMBL26847224 | 0.75 | FABP4 (0.60) | FABP4FABP3MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12186317-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2025-01-07 | — | — | US | disclosed |
| WO-2024240882-A1 | HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR USE IN TREATING ACUTE INFLAMMATION | TES PHARMA S.R.L. (IT) | 2024-11-28 | — | — | WO | disclosed |
| US-20240390371-A1 | HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATING ACUTE INFLAMMATION | TES PHARMA S.R.L. (IT) | 2024-11-28 | — | — | US | disclosed |
| CN-118496217-A | Inhibitors of alpha-amino-beta-carboxyhexadienoic acid semialdehyde decarboxylase | TES制药有限责任公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | US | disclosed |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | US | disclosed |
| US-20220354848-A9 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2022-11-10 | — | — | US | disclosed |
| US-20210379069-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S R L (IT) | 2021-12-09 | — | — | US | disclosed |
| US-20210379069-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S R L (IT) | 2021-12-09 | — | — | US | disclosed |
| EP-3883930-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | Tes Pharma S.r.l. (IT) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354848-A9 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | FABP4 3410/4885FABP3 3995/4885MEN1 2572/4885 |
| US-12186317-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | ACMSD, GLS, ALDH7A1 | FABP4 3410/4885FABP3 3995/4885MEN1 2572/4885 |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | FABP4 3410/4885FABP3 3995/4885MEN1 2572/4885 |
| US-20240390371-A1 | HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATING ACUTE INFLAMMATION | NFKBIA, MPO, LITAF | FABP4 354/4885FABP3 176/4885MEN1 4460/4885 |
| US-20210379069-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | FABP4 3410/4885FABP3 3995/4885MEN1 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.